Survodutide
SYNCHRONIZE™JP
Boehringer Ingelheim · Phase 3 · Completed · Enrollment 274
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Survodutide - 3.6 mg | Obesity or overweight | 3.6 mg | n/r | n/r | n/r |
| Survodutide - 6.0 mg | Obesity or overweight | 6.0 mg | n/r | n/r | n/r |
| Placebo group | Obesity or overweight | n/r | n/r | n/r | n/r |